BDNF and depressive symptom measurement: The major findings of this study include the fact that administration of HJDT during the CUS ameliorated depression-like behaviors, like anhedonia, decreased locomotor activity, despair condition, and cognitive function deficit, which could be relative to the inhibition of microglia activation, following with inflammation reaction inhibition and BDNF-TrkB-CREB pathway upregulation.